<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
<th>Time</th>
<th>Room</th>
<th>Chair</th>
<th>Speaker/Testimonial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Presidential Lecture</td>
<td>Saturday, January 9th, 2021</td>
<td>10:30~11:10</td>
<td>Room1 (4F 41)</td>
<td>Eizo Kaneko</td>
<td>Helicobacter research field is diverse, wide and interesting</td>
</tr>
</tbody>
</table>
|                        |                       |               |               | (Hamamatsu University School of Medicine) | Takahisa Furuta (Center for Clinical Research, Hamamatsu University School of Medicine)
|                        |                       |               |               |                                    | I have studied the detection method of H. pylori by competitive PCR, the influence of H. pylori and its eradication on gastric acid secretion, individual differences in pathophysiology of H. pylori, and the transmission route. We have also studied various regimens for eradication of H. pylori. Through the research on H. pylori, I have met many researchers and have been inspired by them. As noted above, the research field of H. pylori is diverse, wide and interesting. I would like to not only continue this interesting research but also pass it on to many young researchers. |
| Invited Lecture1       | Friday, January 8th, 2021 | 10:35~11:15   | Room1 (4F 41) | Masahiro Asaka                     | Pending paradigm shift in antimicrobial therapy for H. pylori                        |
|                        |                       |               |               | (Health Sciences University of Hokkaido) | David Y. Graham (Baylor College of Medicine, USA)                                     |
| Invited Lecture2       | Friday, January 8th, 2021 | 11:20~12:00   | Room1 (4F 41) | Yoshio Yamaoka                     | Status of H. pylori and Gastric Cancer in Thailand                                  |
|                        |                       |               |               | (Oita University Faculty of Medicine) | Varocha Mahachai, FRCPC, AGAF (Bangkok Hospital&Chulalongkorn University Bangkok, Thailand) |
| Invited Lecture3       | Saturday, January 9th, 2021 | 9:45~10:25    | Room1 (4F 41) | Kentaro Sugano                     | Current situation with regard to Helicobacter pylori infection in Europe             |
|                        |                       |               |               | (Jichi Medical University)          | Francis Mégraud (INSERM U1053, University of Bordeaux & Bacteriology Laboratory, Pellegrin Hospital, France) |
### Keynote Lecture

**Saturday, January 9th, 2021  9:00~9:40  Room3 (4F 43・44)**

<table>
<thead>
<tr>
<th>Chair:</th>
<th>Mitsuru Kaise</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Department of Gastroenterology, Nippon Medical School)</td>
<td></td>
</tr>
</tbody>
</table>

**Virulence factors emerging from comparison of *H. pylori* genomes**

Ichizo Kobayashi  
(University of Tokyo)

### Award ceremony and presentation

**General Chairman:**  
Hiroyoshi Ohta  
(Department of Biomedical Laboratory Sciences, School of Health Sciences, Shinshu University School of Medicine)

### Best Presentation Award

**Friday, January 8th, 2021  13:10~13:40  Room1 (4F 41)**

<table>
<thead>
<tr>
<th>Chair:</th>
<th>Shinichi Takahashi</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Kosei Hospital)</td>
<td></td>
</tr>
</tbody>
</table>

**Successful culture of *Helicobacter suis* strain SNTW101 in vitro and its complete genome sequence.**

Emiko Rimbara  
(Department of Bacteriology II, National Institute of Infectious Diseases)

### Academic Award (Basic Research)

**Friday, January 8th, 2021  13:40~13:55  Room1 (4F 41)**

<table>
<thead>
<tr>
<th>Chair:</th>
<th>Shigeru Kamiya</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Department of Infectious Diseases, Kyorin University School of Medicine)</td>
<td></td>
</tr>
</tbody>
</table>

**Basic study on *Helicobacter pylori* infection and its influencing factors**

Takako Osaki  
(Department of Infectious Diseases, Kyorin University School of Medicine)

### Academic Award (Clinical Research)

**Friday, January 8th, 2021  13:55~14:10  Room1 (4F 41)**

<table>
<thead>
<tr>
<th>Chair:</th>
<th>Yoshihiro Fukuda</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Hyogo College Of Medicine)</td>
<td></td>
</tr>
</tbody>
</table>

**Non-invasive diagnostic methods for *H. pylori* infection**

Tadashi Shinoyama  
(Aomori General Health Examination Center)
Management of gastric cancer in the next decade

Planner: Tomoari Kamada  
(Department of Health Care Medicine, Kawasaki Medical School)

Chair: Mototsugu Kato  
(President of The Japanese Society for Helicobacter Research / Hakodate National Hospital)  
Yasuhiro Kodera  
(President of Japanese Gastric Cancer Association / Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine)

Special Remarks: Hiroyuki Konno  
(Hamamatsu University School of Medicine)

Progress in endoscopic diagnosis of Helicobacter pylori gastritis  
Shoko Ono  
(Department of Gastroenterology, Hokkaido University Hospital, Sapporo, Japan)

Endoscopic diagnosis of gastric cancer using artificial intelligence  
Toshiaki Hirasawa  
(Division of Gastroenterology, Cancer Institute Hospital, Japanese Foundation of Cancer Research)

ESD/EMR guidelines and future perspectives  
Hiroyuki Ono  
(Division of Endoscopy, Shizuoka Cancer Center)

Current status and future prospect of minimally invasive surgery for gastric cancer  
Masanori Terashima  
(Division of Gastric Surgery, Shizuoka Cancer Center)
### Educational Lecture

**Saturday, January 9th, 2021  12:40~13:40  Room1 (4F 41)**

| Chair: | Kiichi Sato  
|        | (Department of Gastroenterology, International University of Health and Welfare Hospital) |

Infection status of *Helicobacter pylori* and risk of gastric cancer  
Shogo Kikuchi  
(Department of Public Health, Aichi Medical University School of Medicine)

Clinical practice of *H. pylori* infection -update-  
Hidekazu Suzuki  
(Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokai University School of Medicine)

### Educational Lecture

**Sunday, January 10th, 2021  10:00~11:00  SALA CITY Hamamatsu (3F Square)**

| Chair: | Hidekazu Suzuki  
|        | (Department of Gastroenterology, Tokai University School of Medicine) |

Infection strategies and host response for *Helicobacter pylori*  
Hitoshi Tsugawa  
(Department of Biochemistry, Keio University School of Medicine)

Diagnosis and treatment of *Helicobacter pylori* infection  
Shin Maeda  
(Department of Gastroenterology, Yokohama City University)
### Morning Seminar

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Room</th>
<th>Chair</th>
<th>Co-sponsored</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, Jan 9th, 2021</td>
<td>8:20~9:00</td>
<td>Room 1 (4F 41)</td>
<td><strong>Ken Haruma</strong> (Kawasaki Medical School and Kawasaki University of Medical Welfare)</td>
<td><strong>MIYARISAN PHARMACEUTICAL CO., LTD.</strong></td>
</tr>
</tbody>
</table>

**Belly bug talks**  
Osamu Handa  
(Division of Gastroenterology, Department of Internal Medicine, Kawasaki Medical School)

### Luncheon Seminar 1

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Room</th>
<th>Chair</th>
<th>Co-sponsored</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday, Jan 8th, 2021</td>
<td>12:10~13:00</td>
<td>Room 1 (4F 41)</td>
<td><strong>Takashi Kawai</strong> (Gastroenterological Endoscopy, Tokyo Medical University)</td>
<td><strong>OLYMPUS CORPORATION</strong></td>
</tr>
</tbody>
</table>

**Latest Gastroscopes and IEE especially in Screening Endoscopy**  
~Not only *Helicobacter Pylori* for Risk Stratification in Endoscopy~  
Katsuhiro Mabe  
(Junpukai Health Maintenance Center Kurashiki)

### Luncheon Seminar 2

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Room</th>
<th>Chair</th>
<th>Co-sponsored</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday, Jan 8th, 2021</td>
<td>12:10~13:00</td>
<td>Room 2 (3F 31)</td>
<td><strong>Hiroyuki Okada</strong> (Department of Gastroenterology and Hepatology, Okayama University Graduate School)</td>
<td><strong>Denka Company Limited</strong></td>
</tr>
</tbody>
</table>

**Gastric cancer screening in the times with COVID-19**  
~including excellent use of serum *H.pylori* antibody~  
Kazuhiko Inoue  
(Junpukai Health Maintenance Center)
### Luncheon Seminar 3

**Friday, January 8th, 2021  12:10~13:00  Room3 (4F 43・44)**

<table>
<thead>
<tr>
<th>Chair:</th>
<th>Kazunari Murakami</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(Department of Gastroenterology Faculty of Medicine)</td>
</tr>
<tr>
<td>Co-sponsored:</td>
<td>Otsuka Pharmaceutical Co., Ltd.</td>
</tr>
</tbody>
</table>

Clinicopathological characteristics of patients with present and past *H. pylori* infection  
Masaaki Kodama  
(Faculty of Welfare and Health Science, Oita University /  
Department of Gastroenterology, Faculty of Medicine, Oita University)

**Forefront of *Helicobacter pylori* diagnosis and treatment-bridging from preventive medicine to clinical practice**  
Tomoari Kamada  
(Department of Health Care Medicine, Kawasaki Medical School General Health Promotion Center, Kawasaki Medical School General Medical Center)

### Luncheon Seminar 4

**Saturday, January 9th, 2021  11:40~12:30  Room1 (4F 41)**

<table>
<thead>
<tr>
<th>Chair:</th>
<th>Kazuma Fujimoto</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(International University of Health and Welfare)</td>
</tr>
<tr>
<td>Co-sponsored:</td>
<td>EIKEN CHEMICAL CO., LTD.</td>
</tr>
</tbody>
</table>

*Helicobacter pylori* test will be important in the coming era of *Helicobacter pylori* negative  
〜Approaching the essence of *H.pylori* test in cancer screening and clinical practice〜  
Katsuhiro Mabe  
(Junpukai Health Maintenance Center kurashiki)

### Luncheon Seminar 5

**Saturday, January 9th, 2021  11:40~12:30  Room2 (3F 31)**

<table>
<thead>
<tr>
<th>Chair:</th>
<th>Mototsugu Kato</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(National Hospital Organization Hakodate Hospital)</td>
</tr>
<tr>
<td>Co-sponsored:</td>
<td>Otsuka Pharmaceutical Co., Ltd. / Takeda Pharmaceutical Company Limited</td>
</tr>
</tbody>
</table>

Clinical practice of upper GI diseases in global eradication situation  
Akiko Shiotani  
(Department of Internal Medicine, Division of Gastroenterology, Kawasaki Medical School)
**Luncheon Seminar 6**

Saturday, January 9th, 2021  11:40~12:30  Room3 (4F 43・44)

Chair: Hiroto Miwa  
(Division of Gastroenterology and Hepatology, Department of Internal Medicine, Hyogo College Of Medicine)

Co-sponsored: FUJIFILM Medical Co., Ltd.

The present situation and prospects of gastritis, the stomach cancer endoscopic diagnosis using LCI/BLI  
~From screening of the lesion to examination~  
Nobuaki Yagi  
(Department of Gastroenterology, ASAHI University Hospital)

**Afternoon Seminar 1**

Friday, January 8th, 2021  14:20~15:10  Room1 (4F 41)

Chair: Naomi Uemura  
(Kohnodai Hospital, National Center for Global Health and Medicine)

Co-sponsored: FUJIFILM Wako Pure Chemical Corporation

How to prevent post eradicated advanced gastric cancer?  
and  
Our experience of L type Wako H. Pylori antibody・J (Latex methods)  
Junko Fujisaki  
(Japanese Foundation For Cancer Reserch, Cancer Insitute Hospital.  
Department of Gastroenterology)

**Afternoon Seminar 2**

Saturday, January 9th, 2021  14:00~14:50  Room1 (4F 41)

Chair: Motoyasu Kusano  
(Gunma University)

Co-sponsored: DAIICHI SANKYO COMPANY, LIMITED / ASTRAZENECA K.K.

Management of gastrointestinal injuries associated with antithrombotic agents  
Tomoki Inaba  
(Kagawa Prefectural Central Hospital)
Usefulness and clinical significance of *H. pylori* serum antibody test

Chair: Kazuhide Higuchi  
(Second Department of Internal Medicine, Osaka Medical College)

Co-sponsored: Denka Company Limited

Evaluation of gastric cancer risk by optimized serum antibody titers against *H. pylori*: a multi-center retrospective study by Research Committee of the Japanese Society for *Helicobacter* Research  
Masanori Ito  
(Department of General Internal Medicine, Hiroshima University Hospital)

Clinical application of anti-*H. pylori* antibody based on the evaluation of 6 serological diagnosis kits using the same samples  
Nobuo Aoyama  
(Aoyama medical clinic)
**Symposium1**

Friday, January 8th, 2021 9:00~10:20  Room2 (3F 31)

**Cutting edge of research for NHPH (Non-**Helicobacter pylori** Helicobacter)**

**Chair:** Emiko Rimbara  
(Department of Bacteriology II, National Institute of Infectious Diseases)  
Masahiko Nakamura  
(Microbial Chemistry, Kitasato University School of Pharmacy)

**S1-01** Clinical characteristics of the cases that *Helicobacter cinaedi* were detected by culture test  
Junichi Iwamoto  
(Department of Gastroenterology and Hepatology, Tokyo Medical University Ibaraki Medical Center)

**S1-02** A case of *Helicobacter heilmannii* sensu stricto-associated gastritis.  
Fumihiko Suenaga  
(Division of Gastroenterology, Matsuyama Red-cross Hospital)

**S1-03** A case of acute gastric mucosal lesion (AGML) caused by acute infection of NHPH  
Toshihisa Tsukadaira  
(Department of Internal Medicine, Kenwakai Hospital)

**S1-04** Outcome of 17 Hospital Survey of Hp-negative and NHPH-positive Patients from 2013 to 2019  
Masahiko Nakamura  
(School of Pharmacy, Kitasato University)

**S1-05** Detection of non-*Helicobacter pylori* helicobacters in porcine samples  
Somay Y. Murayama  
(Nihon University Graduate School of Pharmacy)

**S1-06** Causal relationship between *H. suis* infection and gastric diseases in an experimental mouse model  
Masato Suzuki  
(AMR Research Center, National Institute of Infectious Diseases)

---

**Symposium2**

Friday, January 8th, 2021 10:30~12:00  Room2 (3F 31)

**Acid related disorders after eradication of *H. pylori*: focused on GERD, peptic ulcer, post-bulbar duodenal ulcer, etc.**

**Chair:** Kunio Kasugai  
(Division of Gastroenterology, Department of Internal Medicine, Aichi Medical University School of Medicine)  
Akihito Nagahara  
(Department of Gastroenterology, Juntendo University School of Medicine)

**S2-01** Two cases of eosinophilic esophagitis after goblet gastritis eradication of *Helicobacter pylori*  
Motoyasu Oosawa  
(Division of Gastroenterology, Kawasaki Medical School)
S2-02  Examination of reflux esophagitis before and after *Helicobacter pylori* eradication
Mariko Hojo
(Department of Gastroenterology, Juntendo University School of Medicine)

S2-03  Associated factors of treatment-resistant GERD in patients with reflux esophagitis after eradication
Hideki Mizuno
(Department of Gastroenterology, Toyama City Hospital)

S2-04  The endoscopical findings after *H. pylori* eradication in our medical checkup center
Wataru Inui
(Department of Gastroenterology, Japanese Red Cross Shizuoka Hospital)

S2-05  Evaluation of gastroduodenal ulcer after *Helicobacter pylori* eradication
Akira Koshino
(Department of Gastroenterology, Department of Internal Medicine, Aichi Medical University School of Medicine)

S2-06  Clinical characteristics of peptic ulcer after eradication of *H. pylori*
Rieko Mukai
(Department of Gastroenterology, Asahi University Hospital)

S2-07  Risk of post-bulbar duodenal ulcer after eradication of *H. pylori*
Takahiro Suzuki
(First Department of Medicine, University School of Medicine)

S2-08  Relationship between frailty and abdominal symptom after *H. pylori* eradication
Tsutomu Takeda
(Department of Gastroenterology, Juntendo Tokyo Koto Geriatric Medical Center)

---

**Symposium**

**Friday, January 8th, 2021  13:10 ~ 14:20  Room2 (3F 31)**

**Role and positioning of non-invasive *H. pylori* infection test**

Chair:  Katsuhiko Mabe  
(Junpukai Health Maintenance Center)  
Noriyuki Horiki  
(Gastroenterology and Hepatology, Faculty of Medicine, Mie University Hospital)

---

S3-01  Usefulness and Problems of Diagnosis of *Helicobacter pylori* Infection by Stool Antigen Test
Daisuke Chinda  
(Department of Gastroenterology and Hematology, Hirosaki University Graduate School of Medicine / Department of Community Medicine, Hirosaki University Graduate School of Medicine)

S3-02  Molecular testing based on Qprobe PCR of *H. pylori* in stool which distinguish CAM-resistant variant
Toshihiko Kakiuchi  
(Department of Pediatrics, Faculty of Medicine, Saga University)
**S3-03** Usefulness of evaluating serum pepsinogens in children.
Shin-ichi Fujiwara
(Department of Pediatrics, Sapporo Kosei General Hospital)

**S3-04** Novel kit to detect *H. pylori* DNA and CAM-resistant variant based on Qprobe PCR with gastric wash and stool.
Momoko Tsuda
(Department of Gastroenterology, National Hospital Organization Hakodate National Hospital)

**S3-05** *Helicobacter pylori* screening using antibodies in urine for staff at our hospital
Momoko Tsuda
(Department of Gastroenterology, National Hospital Organization Hakodate National Hospital)

---

**Symposium 4**
Friday, January 8th, 2021  15:20~17:20  Room1 (4F 41)

**Diagnostics of Gastritis: Autoimmune gastritis and *H. pylori* gastritis**

Chair:  Takashi Kawai
(Department of Gastroenterological Endoscopy, Tokyo Medical University Hospital)
Yasuhiko Maruyama
(Department of Gastroenterology, Fujieda Municipal General Hospital)

**S4-Keynote** The Study of AIG from the view point of *H.pylori* infection and Autoimmune Polyglandular Syndrome
Yasuhiko Maruyama
(Department of Gastroenterology, Fujieda Municipal General Hospital)

**S4-01** Differences in clinical findings due to the pathogenesis of autoimmune gastritis
Maiko Kishino
(Institute of Gastroenterology, Tokyo Women’s Medical University)

**S4-02** The relationship between blood, endoscopic findings of autoimmune gastritis and *H. pylori* infection
Masatoshi Sakakibara
(Okazaki City Hospital, Department of Clinical Laboratory)

**S4-03** AIG among the Group D - details of 40 cases of AIG in our transnasal endoscopy center in 2019.
Kazuaki Kawada
(Transnasal Endoscopy Center, Shizuoka Red Cross Hospital)

**S4-04** Endoscopic and histological findings of early autoimmune gastritis including *H.pylori*-infected cases
Tohru Kotera
(Department of Medical Examination, Uji-Tokushukai Medical Center)

**S4-05** Examination of cases of AIG treated with eradication therapy complicated with *H. pylori* infection
Norishige Maiya
(National Hospital Organization Hakodate National Hospital)
S4-06 Clinical analysis of *H. pylori* infection status in patients with autoimmune gastritis
Yuto Sato
(Department of Gastroenterology, Oita University Hospital)

S4-07 A case of gastric cancer in hyperplastic polyp with *Helicobacter pylori*-negative type A gastritis.
Kazuo Kinoshita
(Department of Gastroenterology and Hepatology, Otemae Hospital)

S4-08 Clinical features of patients with AIG and gastric cancer/adenoma at our *H. pylori* special unit
Mihoko Yamade
(First Department of Medicine, Hamamatsu University School of Medicine)

S4-09 The Influence of *H. pylori* Infection on Diagnosis of Autoimmune Gastritis and Gastric Cancer
Marin Ishikawa
(Division of Endoscopy, Hokkaido University Hospital / Department of Gastroenterology, Kushiro Rosai Hospital)

---

**Symposium 5**

Friday, January 8th, 2021  15:20~17:20  Room2 (3F 31)

**Gastrointestinal microbiome research and clinical application based on non-, post- or current *H. pylori* infection**

**Chair:**
Akiko Shiotani
(Division of Gastroenterology, Department of Internal Medicine, Kawasaki Medical School)
Takako Osaki
(Department of Infectious Diseases, Kyorin University School of Medicine)

S5-01 Nitrate-reducing bacteria in the gastric mucosa infected with *H. pylori*.
Hiroyuki Sakae
(Department of Gastroenterology and Hepatology, Okayama University Hospital)

S5-02 Beta diversity and cluster analysis of gastric microbiota in *H. pylori* infected patients
Hideo Yonezawa
(Department of Infectious Diseases, Kyorin University School of Medicine)

S5-03 Examination of gastric microbiota focusing on changes before and after eradication of *H. pylori*
Yuji Nadatani
(Department of Gastroenterology Osaka City University Graduate School of Medicine / Premier Preventive Medicine Osaka City University Graduate School of Medicine)

S5-04 Evaluation of gastric microbiota in autoimmune gastritis
Kengo Tokunaga
(Department of General Medicine, Kyorin University School of Medicine)

S5-05 Gut microbiota among *H. pylori* infected subjects, non-infected subjects and eradication subjects
Chikara Iino
(Department of Gastroenterology and Hematology Hirosaki University Graduate School of Medicine)
**S5-06** Structural changes of gut microbiome after eradication therapy using vonoprazan among teenagers  
Chika Kusano  
(Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine)

**S5-07** Effect of probiotics on gut microbiota in *H. pylori* eradication therapy  
Toshihiko Kakiuchi  
(Faculty of Medicine, Saga University)

**S5-08** Comparative study for changing gut microbiota between dual therapy and conventional triple therapy.  
Toshiki Horii  
(Division of Gastroenterology and Hepatology, Yuri Kumiai General Hospital / Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine)

---

### Symposium 6

**Friday, January 8th, 2021  15:20~17:20  Room3 (4F 43・44)**

**Optimal eradication regimens for *H. pylori* – from standard regimens to rescue regimens**

Chair:  
Makoto Sasaki  
(Division of Gastroenterology, Department of Internal Medicine, Aichi Medical University School of Medicine)

Naohito Shirai  
(Department of Gastroenterology, Enshu Hospital)

Commentator:  
Toshiro Sugiyama  
(Research Division of Molecular Targeting Therapy and Prevention of GI Cancer, Hokkaido University Hospital)

---

**S6-01** Standard panel of drug-resistant *H. pylori* produced by JSHR  
Kenji Yokota  
(Graduate School of Health Science, Okayama University)

**S6-02** The best eradication therapy of *H.pylori* with Clarithromycin resistance in PCAB era  
Chiaki Kusumoto  
(Department of Gastroenterology, Nippon Kokan Fukuyama Hospital / Department of Medical Science and Technology, Hiroshima International University)

**S6-03** A study on *H. pylori* first-line eradication therapy using vonoprazan and drug susceptibility test  
Hiroyuki Nishibayashi  
(Department of Internal Medicine, Kawanishi Municipal Hospital)

**S6-04** Negative interaction with Amoxicillin and Clarithromycin decreases *H. pylori* eradication rates.  
Naohito Shirai  
(Department of Gastroenterology, Enshu Hospital)
Program: Symposium

S6-05  A RANDOMIZED TRIAL OF CLARITHROMYCIN 800 mg VERSUS 400 mg AS PART OF FIRST-LINE TRIPLE THERAPY
Hiroyuki Tamaki
(Department of Gastroenterology, Takamatsu Red Cross Hospital)

S6-06  Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line H. pylori treatment
Masahiko Ohtaka
(Yamanashi Koseiren Health Care center)

S6-07  The situation and problem of the third line Helicobacter pylori eradication therapy in our hospital
Kazunori Adachi
(Department of Gastroenterology, Department of Internal Medicine, Aichi Medical University School of Medicine)

S6-08  Relationship between 3rd-line H. pylori eradication with potent acid inhibition and resistant strain
Mitsushige Sugimoto
(Department of Gastroenterological Endoscopy, Tokyo Medical University Hospital / Division of Digestive Endoscopy, Shiga University of Medical Science Hospital)

S6-09  Comparision of high dose PPI-based and VPZ-based regimens in the third line eradication therapy
Takuma Kagami
(Hamamatsu University School of Medicine)

S6-10  H. pylori Rescue therapy with Vonoprazan, Metronidazole, and Sitafloxacin in Penicillin Allergy case
Soichiro Sue
(Department of Gastroenterology, Yokohama City University Hospital)

S6-11  EVALUATION OF VONOPRAZAN, SITAFLOXACIN AND METRONIDAZOLE REGIMEN FOR PENICILLIN ALLERGY PATIENTS
Kazumi Inokuchi
(Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine)

Symposium 7
Saturday, January 9th, 2021  9:00~11:00  Room2 (3F 31)

Diagnosis and treatment of gastric cancer in the era of H. pylori eradication

Chair: Takuji Gotoda
(Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine)
Mitsushige Sugimoto
(Department of Gastroenterological Endoscopy, Tokyo Medical University Hospital)

S7-01  The characteristics of gastric cancers after H. pylori eradication in our department
Koji Ikegami
(Division of Gastroenterology, Matsuyama Red-cross Hospital)
**S7-02** Characteristics of post-*Helicobacter pylori* eradication gastric cancer in gastric cancer screening  
Kyoko Ito  
(Center for Predictive Medicine, The Jikei University School of Medicine)

**S7-03** Clinicopathological examination of repeated metachronous gastric cancer after *H. pylori* eradication  
Ikko Tanaka  
(Department of Gastroenterology and Hepatology, Hokkaido University Hospital)

**S7-04** Risk factors of metachronous gastric cancer development after eradication of *Helicobacter pylori*  
Masaki Murata  
(Department of Gastroenterology, National Hospital Organization Kyoto Medical Center /  
Department of Gastroenterology, Shiga University of Medical Science Hospital)

**S7-05** Clinicopathological features of scirrhous gastric cancer developed after *H. pylori* eradication  
Ken Namikawa  
(Department of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research)

**S7-06** Influence of *H. pylori* eradication on chemotherapy of advanced gastric cancer patients.  
Tomohiro Higuchi  
(First department of Internal Medicine, Hamamatsu University School of Medicine)

**S7-07** Clinical study of gastric polyps with raspberry-like appearance  
Masahide Fukuda  
(Department of Medicine, Shiga University of Medical Science Hospital)

---

### Symposium8  
**Saturday, January 9th, 2021   9:45~11:15   Room3 (4F 43・44)**

**Latest findings on pathogenicity and pathogenesis of *H. pylori* infection**

<table>
<thead>
<tr>
<th>Chair:</th>
<th>Kinnosuke Yahiro</th>
<th>(Bacteriology, Graduate School of Medicine and School of Medicine, Chiba University)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Hitoshi Tsugawa</td>
<td>(Department of Biochemistry, Keio University School of Medicine)</td>
</tr>
</tbody>
</table>

**S8-01** Geographic diversity and virulence of *Helicobacter pylori* : the Japanese enigma  
Rumiko Suzuki  
(National Institute of Genetics / Oita University Faculty of Medicine)

**S8-02** Mutation diversity of *Helicobacter pylori* on adaptation to the host  
Hitomi Mimuro  
(RIMD, Osaka University)

**S8-03** The *Helicobacter pylori* CagA oncoprotein drives carcinogenesis by inducing genomic instability  
Naoko Kamiya  
(Division of Microbiology, Graduate School of Medicine, The University of Tokyo)
S8-04  Analysis of CD44v9-positive cancer stem cell development by using the organoid-derived mucosoid  
Hitoshi Tsugawa  
(Department of Biochemistry, Keio University School of Medicine)

S8-05  Biphasic effect of Porphyromonas gingivalis LPS on barrier dysfunction after \textit{H. pylori} eradication  
Masayoshi Oriuchi  
(Department of Gastroenterology, TOHOKU University Hospital)

\textbf{Symposium9}  
Saturday, January 9th, 2021  14:50~17:00  Room1 (4F 41)

\textbf{Current status and issues of introduction of an examination and treatment for \textit{H. pylori} infection in school health screening}

\textbf{Chair:}  Taiji Akamatsu  
(Nagano Prefectural Shinshu Medical Center)  
Masumi Okuda  
(Department of Pediatrics, Hyogo College of Medicine)  
\textbf{Commentator:}  Kozo Akino

\textbf{S9-01}  \textit{H. pylori} screening and eradication for junior high school students in Maniwa City  
Hidenori Kondo  
(Department of Internal Medicine, Kondo Hospital)

\textbf{S9-02}  Diagnostic accuracy of antibody test for \textit{Helicobacter pylori} among junior high school students  
Chika Kusano  
(Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine)

\textbf{S9-03}  Current status of \textit{H. pylori} screening for junior high school students in Beppu city.  
Tadayoshi Okimoto  
(Department of Gastroenterology Faculty of Medicine, Oita University)

\textbf{S9-04}  Eradication Project of Gastric Cancer in Nagaoka City  
Takashi Tomidokoro  
(Nagaoka Central General Hospital / Nagaoka City Gastric Cancer Control Council)

\textbf{S9-05}  The results of an anti-\textit{Helicobacter pylori} project in Yokosuka City for eighth-grade students  
Yasuhiro Mizuno  
(Ma-ru Clinic Yokosuka)
Program: Symposium

**S9-06** Changes of urine *H. pylori* antibody test during 2-year interval in junior high school students
Masumi Okuda
(Department of Pediatrics, Hyogo College of Medicine)

**S9-07** Bristol scale evaluation of stool consistency in children undergoing *H. pylori* eradication treatment
Toshihiko Kakiuchi
(Department of Pediatrics, Faculty of Medicine, Saga University)

---

**Symposium10**
Saturday, January 9th, 2021  15:00~17:00  Room3 (4F 43・44)

### Role and positioning of non-invasive *H. pylori* infection test

**Chair:** Masanori Ito  
(Department of General Internal Medicine, Hiroshima University Hospital)  
Tadashi Shimoyama  
(Aomori Ken Sougou Kenshin Center)

**S10-Keynote** Evaluation of gastric cancer risk by optimized serum antibody titers against *H. pylori*: a multi-center retrospective study
Masanori Ito  
(Department of General Internal Medicine, Hiroshima University Hospital)

**S10-01** How should we investigate optimal cutoff of serum *H. pylori* antibody to estimate gastric cancer risk
Shogo Kikuchi  
(Department of Public Health, Aichi Medical University School of Medicine)

**S10-02** Usefulness of the L-type Wako *H. pylori* antibody J test that utilizes latex turbidimetric immunoassay
Yoshitaka Tokai  
(Department of Gastroenterology, Cancer Institute Hospital)

**S10-03** L-type Wako *H. pylori* antibody-J can diagnose correctly with the manufacturer cut-off value
Masayuki Inui  
(Inui Clinic of Internal Medicine)

**S10-04** The utility of L type Wako *H. pylori* antibody J test for gastric cancer risk stratification
Tomoko Yokoyama  
(Fujifilm Nishiazabu Endoscopy Clinic)

**S10-05** Comparison of Anti-*H. pylori* Antibody Detection Kits by Latex Turbidimetric Immunoassay.
Masaaki Kodama  
(Department of Gastroenterology, Oita University / Faculty of Welfare and Health Science, Oita University)

**S10-06** ABC method with new serum pepsinogen cut-off values for diagnosis of *H. pylori* infection
Ryosuke Hirai  
(Department of Gastroenterology and Hepatology, Kurashiki Central Hospital)
$10-07$  Gastric cancer risk estimation ability of *H. pylori* antibody and serum pepsinogen with new criterion
Tae Sasakabe
(Department of Public Health, Aichi Medical University School of Medicine)
## Oral Session 1

**Eradication therapy 1**  
**Friday, January 8th, 2021**  
9:00 ~ 9:25  
Room 3 (4F 43・44)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-1</td>
<td>Comparison of the efficacy of vonoprazan-based eradication therapy for <em>H. pylori</em> infection.</td>
<td>Mariko Hojo (Department of Gastroenterology, Juntendo University School of Medicine)</td>
</tr>
<tr>
<td></td>
<td>Satoru Nakagawa</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(Department of Gastroenterology, Hirosaki University Graduate School of Medicine / Department of Gastroenterology, Tsugaru General Hospital)</td>
<td></td>
</tr>
<tr>
<td>0-2</td>
<td>Comparison of eradication regimens for <em>H. pylori</em> in ≤ 18 years population in Japan</td>
<td>Takeshi Utsunomiya (Department of Pediatrics, Hyogo College of Medicine)</td>
</tr>
<tr>
<td>0-3</td>
<td>Classification of atrophic gastritis with <em>H. pylori</em> infection: evaluation of eradication rate</td>
<td>Kazutake Oguma (Department of Internal Medicine, Asoka Hospital)</td>
</tr>
</tbody>
</table>

## Oral Session 2

**Eradication therapy 2**  
**Friday, January 8th, 2021**  
9:25 ~ 9:50  
Room 3 (4F 43・44)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-4</td>
<td>Recent Trend in <em>H. pylori</em> Eradication Therapy in Kagawa Prefecture</td>
<td>Yoko Saito (Ibarakiken Medical Center)</td>
</tr>
<tr>
<td></td>
<td>Yuichi Hirano</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(Kagawa Prefectural Central Hospital)</td>
<td></td>
</tr>
<tr>
<td>0-5</td>
<td><em>H. pylori</em> eradication rates of P-CAB regimens were not affected by the dosing scheme of AMPC.</td>
<td>Naohito Shirai (Department of Gastroenterology, Enshu Hospital)</td>
</tr>
<tr>
<td>0-6</td>
<td>Eradication of <em>H. pylori</em> using vonoprazan in patients allergic to penicillin.</td>
<td>Tetsu Arai (Department of Gastroenterology and Hematology, Hirosaki University Graduate School of Medicine / Department of Gastroenterology, Aomori Rosai Hospital)</td>
</tr>
</tbody>
</table>
### Oral Session 3

**Friday, January 8th, 2021  9:50~10:15  Room3 (4F 43・44)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-7</td>
<td>Examination of eradication rate and safety using Vonosap in elderly people</td>
<td>Daiki Abe (Department of Gastroenterology, Juntendo Tokyo Koto Geriatric Medical Center / Department of Gastroenterology, Juntendo University School of Medicine)</td>
</tr>
<tr>
<td>0-8</td>
<td>Status of the <em>Helicobacter pylori</em> eradication therapy at our hospital</td>
<td>Kumiko Ueda (Department of Gastroenterology, Juntendo University School of Medicine)</td>
</tr>
<tr>
<td>0-9</td>
<td>Results of <em>Helicobacter pylori</em> eradication therapy using sitafloxacin in our hospital</td>
<td>Tatsushi Omatsu (Department of Gastroenterology, Asahi University Hospital)</td>
</tr>
</tbody>
</table>

### Oral Session 4

**Friday, January 8th, 2021  10:15~10:40  Room3 (4F 43・44)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-10</td>
<td>Usefulness of <em>Helicobacter pylori</em> eradication regimen including vonoprazan in primary therapy</td>
<td>Shu Sahara (Department of Gastroenterology, Hamamatsu Medical Center)</td>
</tr>
<tr>
<td>0-11</td>
<td>Hp resistance rate to MNZ and efficacy of susceptibility test for VPZ-based second line therapy</td>
<td>Toyotaka Kasai (Department of Gastroenterology, Fukaya Red Cross Hospital)</td>
</tr>
<tr>
<td>0-12</td>
<td>Effect of Heat-killed <em>Lactobacillus johnsonii</em> against drug sensitivity of <em>Helicobacter pylori</em></td>
<td>Fuhito Hojo (Institute of Laboratory Animals, Graduate School of Medicine, Kyorin University)</td>
</tr>
</tbody>
</table>
### Oral Session 5

**Friday, January 8th, 2021 10:40~11:05 Room3 (4F 43・44)**

#### Eradication therapy 5

**Chair:** Shotaro Nakamura  
(Division of Gastroenterology, Department of Internal Medicine, Iwate Medical University)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
</tr>
</thead>
</table>
| 0-13 | Study of reliable methods for the detection of *H. pylori* in outpatient clinic.  
Yoshihide Hoshioka  
(Department of Gastroenterology, Second Kawasaki Saiwai Clinic) |
| 0-14 | Analysis of long-term serological and histological changes after eradication of *H. pylori*  
Kensuke Fukuda  
(Department of Gastroenterology, Faculty of Medicine, Oita University) |
| 0-15 | Five-year trend of the cumulative *Helicobacter pylori* eradication rate  
Yuji Shimada  
(Department of Gastroenterology and Hepatology, Juntendo Shizuoka Hospital) |

### Oral Session 6

**Friday, January 8th, 2021 11:05~11:35 Room3 (4F 43・44)**

#### Influence of eradication of *H. pylori*

**Chair:** Tatsuhiko Masaoka  
(Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
</tr>
</thead>
</table>
| 0-16 | Study of association between *H. pylori* infection and colorectal polyp occurrence  
Yoshinari Kawahara  
(Department of Gastroenterology, Faculty of Medicine, Oita University) |
| 0-17 | A case that produced ulcer perforation and performed surgery after the eradication therapy.  
Hiroaki Ito  
(Department of Gastroenterological and General surgery, St.Marianna University School of Medicine Yokohama City Seibu hospital) |
| 0-18 | A study about change of X-ray image between before and after eradication of *Helicobacter pylori*  
Masaru Mizutani  
(Department of internal medicine, Ebara Hospital) |
| 0-19 | Simultaneous stimulation with peptidoglycan and acetaldehyde of oral microbiome might develop gastric carcinogenesis even after successful treatment of *Helicobacter pylori* eradication  
Sujae Lee  
(Division of Gastroenterology, Tohoku University Graduate School of Medicine) |
### Oral Session 7

**Epidemiology and transmission route of *H. pylori***

**Chair:** Toshiaki Shimizu  
(Department of Pediatrics, Juntendo University Faculty of Medicine)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-20</td>
<td>Endoscopic Screening for Gastric Cancer During the Transition Period to a <em>H. pylori</em> Negative Era</td>
<td>Kumiko Yamamoto</td>
<td>Kagawa prefectural central hospital</td>
</tr>
<tr>
<td>0-21</td>
<td>The change of urea breath test results for new adults at a coming-of-age ceremony in Iijima Town.</td>
<td>Akira Horiuchi</td>
<td>Digestive Disease Center, Showa Inan General Hospital</td>
</tr>
<tr>
<td>0-22</td>
<td>Proportion of <em>Helicobacter pylori</em>-uninfected Gastric Mucosa Depending on Birth Year with Fluoroscopy</td>
<td>Yoko Saito</td>
<td>Ibarakiken Medical Center</td>
</tr>
</tbody>
</table>

### Oral Session 8

**Neoplastic lesion related to *H. pylori***

**Chair:** Satoshi Osawa  
(Department of Endoscopic and Photodynamic Medicine, Hamamatsu University School of Medicine)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-23</td>
<td>A case of gastric type adenocarcinoma with intestinal type adenoma in a <em>H. pylori</em>-negative patient</td>
<td>Ryota Uchida</td>
<td>Department of Gastroenterology, Juntendo University, School of Medicine</td>
</tr>
<tr>
<td>0-24</td>
<td>The alteration of antioxidant response involved in an aging and <em>Helicobacter pylori</em> infection.</td>
<td>Tamaki Ikuse</td>
<td>Department of Pediatrics, Juntendo University Faculty of Medicine</td>
</tr>
<tr>
<td>0-25</td>
<td>Three cases of gastric foveolar-type adenomas showing a hyperplastic polyp-like appearance</td>
<td>Shigeto Yoshii</td>
<td>Department of Gastroenterology, Fujieda Municipal General Hospital</td>
</tr>
</tbody>
</table>
Oral Session 9
Friday, January 8th, 2021  13:35 ~ 14:05  Room3 (4F 43・44)

Neoplastic lesion related to *H. pylori* 2
Chair: Ken Sugimoto  
(Division of Gastroenterology, Hamamatsu University School of Medicine)

0-26  Clinical features about advanced gastric cancer without *Helicobacter Pylori* infection  
Junki Tokura  
(Department of Gastroenterology, Cancer Institute Hospital)

0-27  Examination of association between superficial non-ampullary duodenal epithelial tumo and *H. pylori*.  
Shimpei Kawaguchi  
(2nd Department of Internal Medicine, Osaka Medical College)

0-28  A case of gastric MALT lymphoma in which a new lesion appeared 10 years after HP eradication  
Nanae Tsuruoka  
(Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Saga University)

0-29  Analysis of clinicopathologic data and *H. pylori* status in cases operated on for gastric carcinoma  
Atom Katayama  
(Department of Gastrointestinal Surgery, Mitaka Chuo Hospital)

Oral Session 10
Saturday, January 9th, 2021  14:50 ~ 15:15  Room3 (4F 43・44)

Pepsinogen and anti-*H. pylori* antibody
Chair: Shigemi Nakajima  
(JCHO Shiga Hospital)

0-30  Comparison of serum pepsinogen levels between *H.pylori* associated dyspepsia and functional dyspepsia  
Kohei Yasuda  
(Department of Gastroenterology and Hematology, Hirosaki University Graduate School of Medicine)

0-31  *Helicobacter pylori* screening examination of the twenties and thirties The third report  
Hiromi Nishiharai  
(Medical Examination Center Seikei-kai Chiba Medical Center)

0-32  Examination of university freshman positive for pylori infection screening  
Shotaro Okanoue  
(Department of Gastroenterology, Okayama University Hospital)
## Oral Session 11

**Autoimmune gastritis**

**Chair:** Rika Aoki  
(Tokushima Health Screening Center)

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Presenters</th>
</tr>
</thead>
</table>
| 0-33    | Clinical characteristics and serological findings of autoimmune gastritis | Tomoari Kamada  
(Department of Health Care Medicine, Kawasaki Medical School) |
| 0-34    | Cases of autoimmune gastritis in our hospital. | Emiko Uji  
(Department of Gastroenterology, Kawasaki Medical School) |
| 0-35    | Challenging diagnosis of concurrent *H. pylori* infection in cases with pan-atrophic autoimmune gastritis | Tohru Kotera  
(Department of Medical Examination, Uji-Tokushukai Medical Center) |

## Oral Session 12

**Gastritis and Antithrombotic**

**Chair:** Toshihisa Takeuchi  
(Osaka Medical College Hospital, Endoscopy Center)

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Presenters</th>
</tr>
</thead>
</table>
| 0-36    | Improved visibility of the Kyoto Classification of Gastritis evaluated by the patients with LCI | Tsutomu Takeda  
(Department of Gastroenterology, Juntendo Tokyo Koto Geriatric Medical Center) |
| 0-37    | Kyoto classification for gastritis and topographic distribution of neutrophil activity | Osamu Toyoshima  
(Gastroenterology, Toyoshima Endoscopy Clinic / Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo) |
| 0-38    | The effect of anticoagulant agents and *H. pylori* infection on bleeding peptic ulcer | Hideki Ohno  
(Department of Internal Medicine, Tokyo Women’s Medical University Medical Center East) |
I-1  Analysis of association between *Helicobacter pylori* cagA and vacA genes isolated from children with gastritis and duodenal ulcer diseases in Vietnam
Thuy Ha Dang
(Department of Pediatrics, National Hospital of Pediatrics, Hanoi, Vietnam)